BioWorld

Aug. 31, 2005

View Archived Issues

Lack Of 'Strong Efficacy Signal' In Celacade Trial Hurts Vasogen

Shares of Vasogen Inc. tumbled more than 40 percent after the company said it was stopping the Phase III SIMPADICO trial of its Celacade technology in patients with symptomatic peripheral arterial disease (PAD). (BioWorld Today) Read More

After Stock Bounce, Amylin Raises $152M For Pipeline

Read More

ImClone Files Erbitux sBLA For Head And Neck Cancer

Read More

Migenix Starts Confirmatory Phase III Study For MX-226

Read More

NIH Finalizes New Ethics Guidelines, With Changes

Read More

Other News To Note

Read More